Coronavirus Disease 2019 (COVID-19)

This update is current as of 3:00 p.m. on the date it was posted.

NEW FREQUENCY ALERT

As of December 6, 2021 this document will be published on Tuesdays and Fridays. This change reflects the current COVID-19 landscape where the situational updates and guidelines are no longer being released daily by the relevant organizations.*

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents

New Content ........................................................................................................................................... 3
Public Health Agencies .......................................................................................................................... 3
  Public Health Agency of Canada | canada.ca ....................................................................................... 3
  BC Centre for Disease Control | bccdc.ca ....................................................................................... 3
  Institut national de santé publique .................................................................................................... 4
  International (outside of Canada) ....................................................................................................... 4
  CDC: Centers for Disease Control and Prevention | cdc.gov ........................................................................ 4
  ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu .................................................. 4
  FDA: U.S. Food & Drug Administration | fda.gov ............................................................................... 5
  Public Health England | gov.uk ........................................................................................................... 5
  World Health Organization | who.int .......................................................................................................... 5
  Other relevant government bodies / health care organization .......................................................... 6
  CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu .................................................. 7
  National Collaborating Centre for Environmental Health | ncceh.ca ............................................................ 7
  Updated Daily ...................................................................................................................................... 8
  COVID-19 resources (case counts) | arcgis.com ...................................................................................... 8
  COVID-19 Canada Open Data Working Group | COVID-19 CODWG ..................................................... 8
Guidelines and Technical documents (updated weekly) ................................................. 8
Section I: General Guidelines ......................................................................................... 8

Ontario / Canada Main Page ......................................................................................... 8
Reopening/Rebuilding Guidelines .................................................................................. 8
Vaccinations- General ...................................................................................................... 9
Vaccinations- Specific populations .................................................................................. 14
Vaccinations- Adverse Effects ......................................................................................... 16
Background Information/Case Definitions ..................................................................... 17
Laboratories .................................................................................................................... 18
Miscellaneous Guidelines .............................................................................................. 20
Data & Surveillance .......................................................................................................... 21
Variants – Omicron ........................................................................................................... 22
Testing .............................................................................................................................. 23
Symptoms/Treatment ....................................................................................................... 25
COVID-19 Diagnosis in Children ................................................................................... 27
Post-COVID-19 Condition .............................................................................................. 27
Case Investigation & Contact Tracing ............................................................................. 28
Infection Prevention and Control .................................................................................... 29

Section II: Guidelines for Health Sectors ..................................................................... 32

Healthcare Providers ....................................................................................................... 32
First Responders, Dentistry, Pharmacy, and Allied Health ............................................. 33
Death Services .................................................................................................................. 33
Congregate Living (including Long-Term Care, Prisons, and Shelters) ....................... 34

Section III: Guidelines for the Community ................................................................... 36

Travel, Transport & Borders .......................................................................................... 36
Schools / Childcare .......................................................................................................... 37
Mental Health /Addiction /Inequity ................................................................................. 38
Community ....................................................................................................................... 39
Businesses/Workplaces ................................................................................................. 40
Masks (Non-Medical) .................................................................................................... 41
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca

Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- Statement from the Chief Public Health Officer of Canada [12-30-2021]
  - “During the latest 7 day period (Dec 23-29), an average of 25,332 new cases were reported daily across Canada, which is an increase of 141% compared to the previous week. As of December 29, 2021, there have been over 34,000 cases of the Omicron variant reported in 12 provinces and territories; however, these cases likely represent just the tip of the iceberg. Community transmission of Omicron is ongoing in many parts of Canada and outbreaks are being reported in a multiple settings. Omicron is quickly displacing Delta and is now the dominant variant in several jurisdictions. Although the situation is not the same everywhere, the Omicron variant spreads extremely quickly and the local situation can rapidly get out of hand, so increased vigilance is needed across Canada now and in the coming weeks. Accordingly, I am urging all Canadians to continue to reduce their contacts as much as possible. While there is still uncertainty regarding the severity profile of Omicron variant cases, the continued rapid increase in Omicron cases is expected to add an additional strain on the healthcare system, impacting many areas of the country over the coming weeks. Currently, hospitalisation and critical care admission trends are increasing in several jurisdictions. The latest provincial and territorial data show that an average of 1,892 people with COVID-19 were being treated in Canadian hospitals each day during the most recent 7-day period (Dec 23-29), which is 23% higher than last week. This includes, on average, 476 people who were being treated in intensive care units (ICU), 3.7% more than last week and an average of 22 deaths were reported daily (Dec 23-29). Keeping infection rates down remains key to avoiding renewed increases in severe illness trends over the coming weeks and months as well as to ease the longer-term strain on the health system, particularly in heavily impacted areas.”

-Canada COVID-19 weekly epidemiology report: 12 December to 18 December 2021 (week 50) [12-23-2021]
- Vaccine coverage: This report was last updated on December 23, 2021 with data up to and including December 18, 2021.
  - 87.25% of the population 12 years and older are fully vaccinated
  - 39.51 % of the population 5 to 11 years have received at least one dose

Mathematical modelling and COVID-19 [updated regularly]
COVID-19 daily epidemiology update [updated regularly]
COVID-19 data trends [updated regularly]

BC Centre for Disease Control | bccdc.ca

- COVID-19 chain of infection in health care settings poster [01-04-2022]
○ Chain of infection in health care settings (11 X 8.5)
○ Chain of infection in health care settings (11 X 17)

• How is COVID-19 transmitted? Poster [01-04-2022]
  ○ How is COVID-19 transmitted? (11 X 8.5)
  ○ How is COVID-19 transmitted? (11 X 17)

Institut national de santé publique | inspq.qc.ca

• Taux de reproduction (Rt) des cas de SRAS-CoV-2 au Québec [01-03-2022]
• Modélisation de l’évolution de la COVID-19 - rapport du 31 décembre 2021 [12-31-2021]
• Travailleurs essentiels (hors milieux de soins) en isolement : considérations pour un retour au travail devancé dans un contexte de rupture de services [12-29-2021]
• SRAS-CoV-2 : Mesures de prévention et de contrôle des infections dans les milieux de soins pour un cas avec test de dépistage antigénique rapide positif [12-29-2021]

International (outside of Canada)

CDC: Centers for Disease Control and Prevention | cdc.gov

• EARLY RELEASE: Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth — eight integrated health care organizations, United States, December 15, 2020–July 22, 2021 [01-04-2022]
• CDC recommends Pfizer booster at 5 months, additional primary dose for certain immunocompromised children [01-04-2022]
• Stories from the field: examples of successful worker COVID-19 vaccination programs [01-03-2022]
• Reporting COVID-19 vaccinations in the United States [01-03-2022]
• Find out if you can board a flight to the United States [12-31-2021]
• Characteristics and clinical outcomes of children and adolescents aged <18 years hospitalized with COVID-19 — six hospitals, United States, July–August 2021 [12-30-2021]
• Interim estimate of vaccine effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection among adolescents aged 12–17 years — Arizona, July–December 2021 [12-30-2021]
• COVID-19 vaccine safety in children aged 5–11 years — United States, November 3–December 19, 2021 [12-30-2021]
• Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) variant cluster — Nebraska, November–December 2021 [12-30-2021]
• Evaluation of test to stay strategy on secondary and tertiary transmission of SARS-CoV-2 in K–12 schools — Lake County, Illinois, August 9–October 29, 2021 [12-30-2021]
• Evaluation of a test to stay strategy in transitional kindergarten through grade 12 schools — Los Angeles County, California, August 16–October 31, 2021 [12-30-2021]
• COVID-19 vaccines for people with underlying medical conditions [12-30-2021]
• Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-US healthcare settings [12-30-2021]

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu

• Data on the daily number of new reported COVID-19 cases and deaths by EU/EEA country [01-04-2022]
At the end of week 50 (week ending Sunday 19 December 2021), the overall epidemiological situation in the EU/EEA is characterised by a high overall case notification rate which appears to have peaked in the last two weeks and a death rate which has stabilised following a prolonged period of slow increase. High case notification rates or an epidemiological situation of high concern are observed in most EU/EEA Member States. This situation is largely driven by the high transmissibility of the Delta variant, increased spread of Omicron in some countries, and the recent strengthening of non-pharmaceutical interventions in many countries.

The overall COVID-19 case notification rate for the EU/EEA was 756.2 per 100 000 population (801.3 the previous week). This rate has been decreasing for one week. The 14-day COVID-19 death rate (59.0 deaths per million population, compared with 59.2 deaths the previous week) has been stable for four weeks. Of 29 countries with data on hospital or ICU admissions or occupancy up to week 50, nine reported an increasing trend in at least one of these indicators compared to the previous week.

FDA: U.S. Food & Drug Administration | fda.gov

- Coronavirus (COVID-19) update: daily roundup [updated regularly]
- FDA takes multiple actions to expand use of Pfizer-BioNTech COVID-19 vaccine [01-03-2022]
- FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma [12-28-2021]
- SARS-CoV-2 viral mutations: impact on COVID-19 tests [12-28-2021]

Public Health England | gov.uk

Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”.

- Location of Public Health England (PHE) functions from 1 October 2021

World Health Organization | who.int

- WHO Director-General’s opening remarks at the press conference [12-29-2021]
  - “I still remain optimistic that this can be the year we not only end the acute stage of the pandemic but we also chart a path to stronger health security. Building on the successes and failures we must not only share vaccines faster and more equitably with COVAX and AVAT, we must support countries in manufacturing and rolling them out to everyone. And access to new treatments must also follow. This virus will continue to evolve and threaten our health systems if we don’t improve the collective response. Right now, Delta and Omicron are twin threats that are driving up cases to record numbers, which again is leading to spikes in hospitalisations and deaths. I am highly concerned that Omicron being more transmissible, circulating at the same time as Delta - is leading to a tsunami of cases. This is and will continue to put immense pressure on exhausted health workers and health systems on the brink of collapse and again disrupting lives and livelihoods. The pressure on health systems is not only because of new COVID-19 patients requiring hospitalisation but also a large number of health workers are getting sick themselves. The unvaccinated are many times more at risk of dying from either
variant. Omicron is moving so quickly, in addition to vaccination, public health social measures are also needed to stem the wave of infection, protect health workers and systems, open up societies and keep children in school. I welcome innovative solutions to reaching vulnerable communities that have not received vaccination yet because the primary doses are the most important for people to develop immunity. Bottom-up microplanning with strong community engagement and mobile vaccination teams, which have been highly effective in ridding most of the world of polio, are another way to get vaccines to the hard-to-reach. WHO will support countries as they look to improve access to COVID-19 tools and catch up with routine immunisation.”

- **Together on the road to evidence-informed decision-making for health in the post-pandemic era: new EVIPNet Call for Action** [12-30-2021]
- **Coronavirus disease (COVID-19) weekly epidemiological update** [12-28-2021]
- **Medical equipment related to oxygen therapy – cleaning – task sequence** [12-28-2021]
- **Care, cleaning and disinfection of respiratory equipment in sterile services department** [12-28-2021]
- **Checklists for care, cleaning, disinfection and sterilization of respiratory devices** [12-28-2021]
- **Log of major changes and errata in WHO daily aggregate case and death count data** [updated regularly]
- **Draft landscape and tracker of COVID-19 candidate vaccines** [updated regularly]
- **Coronavirus disease (COVID-2019) press briefings** [audio posted first; transcripts posted later]
- **Timeline: WHO's COVID-19 response** [updated regularly]
- **EPI-WIN: WHO information network for epidemics** [updated regularly]

**Other relevant government bodies / health care organization**

- **Government of Ontario**
  - [Ontario temporarily moving to modified Step Two of the Roadmap to Reopen](#) [01-03-2022]
  - [Updated eligibility for PCR testing and case and contact management guidance in Ontario](#) [12-30-2021]
  - [Ontario updating public health measures and guidance in response to Omicron](#) [12-30-2021]
  - [Ontario taking further action to keep long-term care residents safe](#) [12-28-2021]
- **Indigenous Services Canada**
  - [Coronavirus (COVID-19) and Indigenous communities](#) [updated regularly]
- **Statistics Canada**
  - [COVID-19: a data perspective](#) [updated regularly]
  - [COVID-19 in Canada: year-end update on social and economic impacts](#) [12-22-2021]
- **UK Health Security Agency**
  - [COVID-19: management of staff and exposed patients and residents in health and social care settings](#) [updated 12-30-2021]
  - [COVID-19: guidance for households with possible coronavirus infection](#) [updated 12-30-2021]
  - [Visiting arrangements in care homes](#) [updated 12-30-2021]
  - [COVID-19 surveillance and immunity studies](#) [updated 12-29-2021]
  - [COVID-19 test validation approved products](#) [updated 12-29-2021]
- **UK Department for Education**
Actions for schools during the coronavirus outbreak [updated 01-02-2022]
Higher education providers: coronavirus (COVID-19) [updated 01-02-2022]
Guidance for parents and carers of children attending out-of-school settings during the coronavirus (COVID-19) outbreak [updated 01-02-2022]
Protective measures for holiday or after-school clubs and other out-of-school settings for children during the coronavirus (COVID-19) outbreak [updated 01-02-2022]
What parents and carers need to know about early years providers, schools and colleges during COVID-19 [updated 01-02-2022]
Special schools and other specialist settings: coronavirus (COVID-19) [updated 01-02-2022]
Critical workers and vulnerable children who can access schools or educational settings [updated 01-02-2022]

UK Medicines and Healthcare products Regulatory Agency
How tests and testing kits for coronavirus (COVID-19) work [updated 12-29-2021]
Centre for Global Infectious Disease Analysis
Report 50 - Hospitalisation risk for Omicron cases in England [12-22-2021]

CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu
FDA authorizes Pfizer booster dose for 12 to 17 year-olds [01-03-2022]
Pfizer COVID-19 vaccine safe in those 5 to 11, 92% effective in adolescents [01-03-2022]
COVID activity ramps up in India, Middle East [01-03-2022]
Omicron cases pick up pace as world enters pandemic year 3 [12-29-2021]
A third of Ohio deer test positive for COVID-19 virus [12-29-2021]
News Scan for Dec 29, 2021: Shorter Omicron incubation period; Weight loss surgery and COVID severity; Antibiotic use in Latin American hospitals; Flu and COVID cocirculation in the Americas
Shortened CDC COVID isolation guide draws sharply mixed reviews [12-28-2021]
Medicare data spotlight deadly impact of COVID-19 on Hispanics [12-28-2021]
News Scan for Dec 28, 2021: Breakthrough COVID and immune dysfunction; Omicron-neutralizing antibody findings; Racial disparities in antibiotic choice; First Ohio Powassan virus case

National Collaborating Centre for Environmental Health | ncceh.ca
The Omicron wave – communicating during uncertainty [12-21-2021]
December, 2021 Environmental Health Research Scan (with COVID-19 section)
November, 2021 Environmental Health Research Scan (with COVID-19 section)
October, 2021 Environmental Health Research Scan (with COVID-19 section)

ProMED | promedmail.org
Latest on COVID-19 [individual posts]
COVID-19 update (04): USA, reinfection, young adult, comment [01-03-2022]
COVID-19 update (03): Antarctica, omicron, S Africa, China [01-02-2022]
COVID-19 update (02): South Africa, France, UK, test protocols [01-02-2022]
- COVID-19 update (01): omicron severity & changes, Germany, T-cell reactivity [01-01-2022]
- COVID-19 update (452): rapid test, omicron, Ab neutralization, school, WHO [12-30-2021]
- COVID-19 update (451): animal, USA, wild deer [12-30-2021]
- COVID-19 update (450): maternal Abs, CDC isolation guidance, WHO [12-30-2021]

Updated Daily

COVID-19 resources (case counts) | arcgis.com
- Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
- 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
- Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org
- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
- Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
- Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated weekly)
The guidelines listings are current to 12-22-2021; posted 12-23-2021

Section I: General Guidelines

Ontario / Canada Main Page
- Ontario guidance
- Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario
- ON A plan to safely reopen Ontario and manage COVID-19 for the long-term [no date]
- ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)
- CA COVID-19: Readiness criteria and indicators for easing restrictive public health measures [updated 05-14-2021]
• BC BC’s restart: a plan to bring us back together [12-17-2021]
• AB COVID-19 public health actions [no date]
• SK Public health measures [no date]
• MB Manitoba Pandemic Response System [no date]
• QC About the measures in force [no date]
• NB Living with COVID-19 [no date]
• NL Alert level system [no date]
• PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
• NS Coronavirus (COVID-19): restrictions and guidance [updated regularly]
• NW Emerging wisely 2021 [no date]
• YT Forging ahead: the Yukon’s continuing response to COVID-19 [no date]
• NT Nunavut’s Path: Living with COVID-19 [no date]
• PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
• NL Alert level system [no date]
• WHO Implementation guidance for assessments of frontline service readiness [07-01-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19: Interim guidance [06-14-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [11-04-2020]
• WHO COVID-19 Preparedness and Response Progress Report - 1 February to 30 June 2020 [08-03-2020]

WHO
• Implementation guidance for assessments of frontline service readiness [07-01-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19: Interim guidance [06-14-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19 [11-04-2020]
• WHO COVID-19 Preparedness and Response Progress Report - 1 February to 30 June 2020 [08-03-2020]

UK
• Reopening businesses and venues in England [updated 12-14-2021]
• Coronavirus (COVID-19): guidance on the phased return of elite sport [updated 12-13-2021]
• Our plan to rebuild: the UK government’s COVID-19 recovery strategy [07-24-2020]

ECDC
• Data on country response measures to COVID-19 [updated 12-09-2021]
• Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations- General

Ontario Ministry of Health
• COVID-19 Vaccine-relevant information and planning resources [updated 12-17-2021]
• Guidance for Routine Immunization Services During COVID-19 Version 2 [10-28-2021]
• Ethical framework for COVID-19 vaccine distribution [updated 09-23-2021]

Canada (Federal)
• Planning guidance for immunization clinics for COVID-19 vaccines [12-17-2021]
• Adjusting public health measures in the context of COVID-19 vaccination [modified 12-16-2021]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• **Summary of NACI rapid response of December 3, 2021: Guidance on booster COVID-19 vaccine doses in Canada** [12-03-2021]
• **NACI interim guidance on booster COVID-19 vaccine doses in Canada** [10-29-2021]
• ** Archived: Summary of National Advisory Committee on Immunization (NACI) statement: Recommendations on the use of COVID-19 vaccines** [modified 10-22-2021]
• **Quick reference guide on use of COVID-19 vaccines: Overview** [modified 10-13-2021]
• ** Archived: Guidance on the prioritization of initial doses of COVID-19 vaccine(s)** [09-21-2021]
• ** Archived: Guidance for influenza vaccine delivery in the presence of COVID-19** [09-13-2021]
• **For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines** [09-16-2021]
• **COVID-19 immunization: federal, provincial and territorial statement of common principles** [modified 08-11-2021]
• **Health care provider vaccine tool kit, version 2** [05-07-2021]
• **Planning guidance for administration of COVID-19 vaccine** [12-21-2020]
• **Canada’s COVID-19 immunization plan: saving lives and livelihoods** [no date]
• **Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic** [10-14-2020]
• **Interim guidance on continuity of immunization programs during the COVID-19 pandemic** [05-13-2020]

**Provinces and territories (other than Ontario)**

• **BC COVID-19 Vaccine Eligibility** [updated 12-15-2021]
• **BC COVID-19 Vaccine ChAdOx1-S [recombinant]** [updated 12-15-2021]
• **BC Vaxzevria™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)** [updated 12-15-2021]
• **BC COVID-19 Vaccine Screening Checklist** [12-07-2021]
• **BC COVID-19 mRNA Vaccine Spikevax™ (Moderna)** [updated 12-07-2021]
• **BC COVID-19 mRNA Vaccine Comirnaty™ (Pfizer-BioNTech)** [updated 12-07-2021]
• **BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines** [updated 12-07-2021]
• **BC Janssen Shipping, Storage and Use Guideline** [updated 11-23-2021]
• **BC 2021/22 Seasonal Influenza Vaccine Eligibility** [10-00-2021]
• **BC Immunization Manual: Summary of changes: Admin circular** [10-19-2021]
• **BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines** [updated 10-15-2021]
• **BC Moderna Redistribution Guidelines** [updated 10-15-2021]
• **BC Pfizer Redistribution Guidelines** [updated 10-15-2021]
• **BC Point of Care Risk Assessment (PCRA)** [no date]
• **BC Latex Content in Vaccines** [updated 10-00-2021]
• **BC COVID-19 Vaccination Status Information and Preventive Measures Order** [10-06-2021]
• **BC Immunization manual appendix A: informed consent (page 4)** [updated 09-00-2021]
• **BC Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine (including dry ice procedures)** [08-31-2021]
• **BC COVID-19 vaccination: why your 2nd dose is important** [updated 08-27-2021]
• **BC Pfizer vaccine sub dose vial reporting** [07-13-2021]
WHO

- Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [12-09-2021]
- Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [12-09-2021]
- Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [12-07-2021]
- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [12-05-2021]
- Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
- Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 [11-03-2021]
- Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: Grading of evidence – Evidence to recommendations tables [11-03-2021]
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [10-28-2021]
- Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
- Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [10-21-2021]
- Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables [10-21-2021]
- Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) [08-04-2021]
- Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [07-30-2021]
- Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience) [07-30-2021]
- COVID-19 vaccine introduction and deployment costing tool (CVIC tool) version 2.2 [06-10-2021]
- Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [06-01-2021]
• Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: [06-01-2021]
• Technical note on delayed shipments for the ChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses?: Scientific brief [05-26-2021]
• Health worker communication for COVID-19 vaccination flow diagram [05-13-2021]
• AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer [05-10-2021]
• AstraZeneca ChAdOx1-S [recombinant], COVID-19 vaccine [05-10-2021]
• Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design [05-07-2021]
• COVID-19 exercise programme - drills for vaccine deployment [05-03-2021]
• Why are there extra doses of vaccine in the vaccine vial? [04-16-2021]
• COVID-19 and mandatory vaccination: ethical considerations and caveats [04-13-20231]
• Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
• Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC
• Communication Resources for COVID-19 Vaccines [12-11-2021]
• COVID-19 vaccine booster shot [updated 12-09-2021]
• COVID-19 vaccination clinical & professional resources [updated 12-01-2021]
• Interim public health recommendations for fully vaccinated people [updated 11-19-2021]
• COVID-19 vaccine reporting systems [11-15-2021]
• COVID-19 vaccination program operational guidance [updated 10-14-2021]
• Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 09-10-2021]
• Public health investigations of COVID-19 vaccine breakthrough cases: Case investigations protocol [no date]
• Interim guidance for routine and influenza immunization services during the COVID-19 Pandemic [04-15-2021]
• Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization [04-14-2021]

UK
• COVID-19 vaccination: information for healthcare practitioners [updated 12-21-2021]
• National protocol for Comirnaty® COVID-19 mRNA vaccine [updated 12-18-2021]
• National protocol for Spikevax (formerly COVID-19 Vaccine Moderna) [12-17-2021]
• Monitoring reports of the effectiveness of COVID-19 vaccination [updated 12-16-2021]
• COVID-19 vaccination programme [updated 12-14-2021]
• COVID-19: the green book, chapter 14a [updated 12-14-2021]
• COVID-19 vaccination: booster dose resources [updated 12-11-2021]
• National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [updated 11-20-2021]
• COVID-19 vaccination: what to expect after vaccination [updated 11-09-2021]
• National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [10-29-2021]
• Monitoring of the effectiveness of COVID-19 vaccination [updated 09-14-2021]
• COVID-19 vaccination: blood clotting information for healthcare professionals [updated 09-03-2021]
• COVID-19 vaccination: vaccine product information [06-14-2021]
• COVID-19: vaccine surveillance strategy [03-29-2021]

ECDC

• Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA [12-14-2021]
• Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA [11-11-2021]
• Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA [10-15-2021]
• Infographic: Facilitating COVID-19 vaccination acceptance and uptake [10-15-2021]
• Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0 [10-08-2021]
• Interim public health considerations for the provision of additional COVID-19 vaccine doses [09-01-2021]
• Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence [07-22-2021]
• Countering online vaccine misinformation in the EU/EEA [06-29-2021]
• Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making [05-18-2021]
• Objectives of vaccination strategies against COVID-19 [04-23-2021]
• Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions [04-21-2021]
• Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice [03-29-2021]
• Stress test on logistical aspects of COVID-19 vaccination deployment plans: final report [02-03-2021]
• Integrated COVID-19 response in the vaccination era [02-01-2021]
• COVID-19 vaccination and prioritisation strategies in the EU/EEA [12-22-2020]

Australia

• COVID-19 vaccination – information on COVID-19 Pfizer (COMIRNATY) vaccine [updated 12-21-2021]
• COVID-19 vaccination – clinical advice on the use of a different COVID-19 vaccine as the second dose [updated 12-15-2021]
• COVID-19 vaccination – vaccine dose policy [updated 12-14-2021]
• COVID-19 vaccination – ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021 [updated 10-29-2021]
• COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination 10-14-2021]
• Op COVID SHIELD national COVID vaccine campaign plan [updated 08-03-2021]
• COVID-19 vaccination – updated provider kit for general practices [07-08-2021]
Vaccinations - Specific populations

Canada (Federal)
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [updated 12-16-2021]
- COVID-19: Recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [updated 12-10-2021]
- Archived: National Advisory Committee on Immunization (NACI) rapid response: additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2-dose primary series [12-03-2021]
- NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- NACI rapid response: booster dose in long-term care residents and seniors living in other congregate settings [12-03-2021]
- National Advisory Committee on Immunization (NACI) statement: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [modified 11-25-2021]
- Archived: Preliminary guidance on key populations for early COVID-19 immunization [modified 09-21-2021]
- Archived: Guidance on the prioritization of key populations for COVID-19 immunization [02-12-2021]

Provinces and territories (other than Ontario)
- BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) adult/adolescent [updated 12-07-2021]
- BC COVID-19 vaccines for pregnant people with heart disease [updated 12-04-2021]
- BC Clinical guidance on COVID-19 vaccines for people with metabolically unstable inborn errors of metabolism (IEM) [updated 12-04-2021]
- BC Clinical guidance on COVID-19 vaccines for people with thalassemia [updated 12-04-2021]
- BC Clinical guidance on COVID-19 vaccines for people with cystic fibrosis [updated 12-04-2021]
- BC Clinical guidance on COVID-19 vaccines for people with sickle cell disease [updated 12-04-2021]
- BC Clinical guidance on COVID-19 vaccines for people with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) [updated 12-04-2021]
- BC Clinical guidance on COVID-19 vaccines for persons with autoimmune rheumatic diseases updated [12-04-2021]
- BC Clinical guidance on COVID-19 vaccines for persons with inflammatory bowel disease [updated 12-04-2021]
• BC Clinical guidance on COVID-19 vaccines for people with kidney disease (dialysis, non-dialysis with advanced disease, glomerulonephritis) [updated 12-04-2021]
• BC Clinical guidance on COVID-19 vaccines for solid organ transplant recipients [updated 12-04-2021]
• BC Clinical guidance on COVID-19 vaccines for people with splenectomy or functional asplenia [updated 12-04-2021]
• BC Clinical guidance on COVID-19 vaccines for people with hematological malignancy at any stage of treatment and/or who have undergone hematopoietic stem cell transplant or CAR-T cell therapy in the past 6 months [updated 12-04-2021]
• BC Clinical guidance on COVID-19 vaccines for people with hematological malignancy at any stage of treatment and/or who have undergone hematopoietic stem cell transplant or CAR-T cell therapy in the past 6 months [updated 12-04-2021]
• BC Clinical guidance on COVID-19 vaccines for people with solid cancers [12-04-2021]
• BC Clinical guidance on COVID-19 vaccines for people with autoimmune neuromuscular disorders receiving immunosuppressive/immunomodulating therapy [09-20-2021]
• BC FAQ: providing care to pregnant patients and their newborns during the COVID-19 pandemic [06-30-2021]
• BC Clinical guidance on COVID-19 vaccines for people with significant neuromuscular conditions who require respiratory support [06-17-2021]

WHO
• Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-25-2021]
• Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]
• Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 [04-26-2021]

CDC
• COVID-19 vaccine information for specific groups [updated 12-14-2021]
• COVID-19 vaccines for children and teens [updated 12-13-2021]
• COVID-19 vaccination considerations for persons with underlying medical conditions [updated 12-15-2021]
• COVID-19 vaccines for people who would like to have a baby [updated 12-06-2021]
• How to talk with parents about COVID-19 vaccination [updated 11-29-2021]
• COVID-19 vaccine equity for racial and ethnic minority groups [11-02-2021]
• Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access [updated 08-26-2021]
• Guidance for vaccinating older adults and people with disabilities at vaccination sites [08-10-2021]
• Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [4-30-2021]

UK
• COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding [12-20-2021]
• COVID-19 vaccination: guide for adults [updated 12-09-2021]
Vaccinations - Adverse Effects

Canada (Federal)
- National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Reports of myocarditis and pericarditis after COVID-19 vaccination: Communiqué to health practitioners (June 3, 2021) [06-14-2021]

Provinces and territories (other than Ontario)
- BC Guidance document on the management of inadvertent vaccine errors [12-07-2021]
- BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
- BC Adverse event following immunization with COVID-19 vaccine case report form [10-12-2021]
- BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
- BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]
• BC Clinical care guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome (TTS) [04-30-2021]

CDC
• Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [reviewed 08-09-2021]

WHO
• How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
• COVID-19 Vaccines: safety surveillance manual. Module on safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women [07-12-2021]
• How to monitor and report COVID-19 vaccine side effects [03-15-2021]

UK
• Coronavirus (COVID-19) vaccine adverse reactions [12-16-2021]
• Myocarditis and pericarditis after COVID-19 vaccination [12-07-2021]
• COVID-19 vaccination: Guillain-Barré Syndrome information for healthcare professionals [12-17-2021]
• Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

Australia
• COVID-19 vaccination – Guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [12-02-2021]
• COVID-19 vaccination – Primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine [09-25-2021]

Background Information/Case Definitions

Ontario Ministry of Health
• Ontario case definition - coronavirus disease (COVID-19) [05-21-2021]

PHAC
• National case definition: coronavirus disease (COVID-19) [updated 12-20-2021]
• COVID-19 case report form [02-15-2021]

CDC
• Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

WHO
• A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
• Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]
• Rapid risk assessment: increased transmission of COVID-19 in the EU/EEA and the UK – thirteenth update [10-23-2020]

UK
• COVID-19: background information [10-06-2021]
Laboratories

Ontario Ministry of Health

- COVID-19 provincial testing guidance update V. 14.0 [updated 11-10-2021]
- Community labs and specimen collection centres: version 3 [03-29-2020]

PHAC

- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [11-23-2021]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [04-28-2020]

WHO

- Acknowledgements: The Unity Studies for sero-epidemiological investigation of COVID-19 [12-14-2021]
- Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
- Laboratory biosafety guidance related to coronavirus disease (COVID-19) [01-28-2021]
- COVID-19 new variants: knowledge gaps and research [01-12-2021]
- Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
- SARS-CoV-2 genomic sequencing for public health goals [01-08-2021]
- SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide [12-21-2020]
- Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
- Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
- Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays [09-11-2020]

CDC

- Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19) [12-13-2021]
- Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19) [updated 12-13-2021]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [updated 12-13-2021]
• **Testing strategies for SARS-CoV-2** [updated 12-07-2021]
• **Frequently asked questions on COVID-19 testing for laboratories** [updated 11-12-2021]
• **How to report COVID-19 laboratory data** [updated 11-03-2021]
• **Science Brief: SARS-CoV-2 infection-induced and vaccine-induced immunity** [10-29-2021]
• **Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19** [10-25-2021]
• **Evaluation for SARS-CoV-2 testing in animals** [10-12-2021]
• **Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings** [updated 09-21-2021]
• **Using antibody tests for COVID-19** [updated 09-10-2021]
• **Guidance for general laboratory safety practices during the COVID-19 pandemic** [updated 08-19-2021]
• **Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination** [reviewed 08-09-2021]
• **Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing** [updated 06-30-2021]
• **Guidance for reporting SARS-CoV-2 sequencing results** [06-23-2021]
• **Genomic Surveillance for SARS-CoV-2 variants** [06-17-2021]
• **Resources for laboratories working on coronavirus (COVID-19)** [03-28-2021]
• **Information for laboratories about coronavirus (COVID-19)** [03-28-2021]
• **SARS-CoV-2 viral culturing at CDC** [12-29-2020]
• **Serology testing for COVID-19 at CDC** [11-03-2020]

**UK**

• **Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [updated 12-01-2021]
• **Technical validation protocol for SARS-CoV-2 nucleic acid detection** [updated 12-01-2021]
• **National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests** [updated 12-01-2021]
• **Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [updated 12-01-2021]
• **NHS test and trace statistics (England): methodology** [updated 11-18-2021]
• **How tests and testing kits for coronavirus (COVID-19) work** [11-11-2021]
• **Coronavirus (COVID-19) testing in adult care homes** [updated 09-29-2021]
• **Surge testing for new coronavirus (COVID-19) variants** [updated 08-16-2021]
• **Maintaining records of staff, customers and visitors to support NHS Test and Trace** [07-20-2021]
• **COVID-19: guidance for sampling and for diagnostic laboratories** [03-29-2021]

**ECDC**

• **The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates** [05-10-2021]

**Australia**
• **PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19)** [11-02-2021]

Other

• **BC PHO order on health authority regulated health professionals SARS-CoV-2 swabbing** [11-16-2020]
• **BC PHO order on midwives and certified practice speech language pathologists SARS-CoV-2 swabbing** [11-16-2020]
• **BC PHO order on British Columbia emergency health services SARS-CoV-2 swabbing** [11-16-2020]

**Miscellaneous Guidelines**

**PHAC**

• **Individual and community-based measures to mitigate the spread of COVID-19 in Canada** [modified 12-16-2021]
• **COVID-19: Safety advice for private indoor gatherings** [12-09-2021]
• **Federal/provincial/territorial public health response plan for ongoing management of COVID-19** [09-16-2021]
• **COVID-19 and people with disabilities in Canada** [06-21-2021]

**Canadian provinces and territories (other than Ontario)**

• **BC COVID-19 ethical decision-making framework** [12-24-2020]

**WHO**

• **WHO technical consultation on oxygen access scale-up for COVID-19** [07-14-2021]
• **Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition** [07-09-2021]
• **Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance** [06-14-2021]
• **Critical preparedness, readiness and response actions for COVID-19: interim guidance** [05-27-2021]
• **WHO-convened global study of origins of SARS-CoV-2: China Part** [03-30-2021]
• **Practical actions in cities to strengthen preparedness for the COVID-19 pandemic and beyond** [07-17-2020]
• **Investing in and building longer-term health emergency preparedness during the COVID-19 pandemic** [07-06-2020]
• **Considerations on Indigenous Peoples, Afro-Descendants, and other ethnic groups during the COVID-19 Pandemic, 4 June 2020** [06-04-2020]
• **Policy brief: COVID-19 and people on the move** [06-00-2020]

**CDC**

• **Public health guidance for potential COVID-19 exposure associated with travel** [12-02-2021]
• Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [updated 09-10-2021]
• RRT composition: COVID-19 considerations [03-01-2021]
• Public health guidance for community-related exposure [03-01-2021]
• Wildfire smoke and COVID-19: frequently asked questions and resources for air resource advisors and other environmental health professionals [10-09-2020]
• Managing investigations during an outbreak [07-31-2020]
• Optimizing supply of PPE and other equipment during shortages [07-16-2020]

ECDC
• COVID-19 – high risk shielded patient list identification methodology. Version 12 [12-08-2021]
• One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
• Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]
• Conducting in-action and after-action reviews of the public health response to COVID-19 [06-04-2020]

Australia
• CDNA National guidelines for public health units [updated 12-09-2021]

Other
• Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [11-30-2021]

Data & Surveillance

Canada
• COVID-19 data trends [modified 12-17-2021]
• Mathematical modelling and COVID-19 [modified 12-10-2021]
• National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO
• Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States [12-17-2021]
• WHO SPRP 2021 Mid-term Report - WHO Strategic Action Against COVID 19 [10-07-2021]
• WHO COVID-19 SPRP: updated appeal September 2021 - March 2022 [10-07-2021]
• Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021 [08-09-2021]
• WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [04-14-2021]
• Public health surveillance for COVID-19: interim guidance [12-16-2020]
• Corrigenda – maintaining surveillance of influenza and monitoring SARS-CoV-2 [12-03-2020]
• Maintaining surveillance of influenza and monitoring SARS-CoV-2 – adapting Global Influenza surveillance and Response System (GISRS) and sentinel systems during the COVID-19 pandemic [11-19-2020]
• Status of environmental surveillance for SARS-CoV-2 virus – scientific brief [08-07-2020]
• Global surveillance of COVID-19: WHO process for reporting aggregated data [08-07-2020]
• Estimating mortality from COVID-19 [08-04-2020]
• Surveillance strategies for COVID-19 human infection. Update 29 [06-05-2020]
• Surveillance protocol for SARS-CoV-2 infection among health workers [05-28-2020]

CDC
• Wastewater surveillance data reporting & analytics [11-08-2021]
• National wastewater surveillance system (NWSS) [07-21-2021]
• Wastewater surveillance testing methods [06-23-2021]
• Public health interpretation and use of wastewater surveillance data [06-23-2021]
• Developing a wastewater surveillance sampling strategy [06-23-2021]
• Targeted wastewater surveillance at facilities, institutions, and workplaces [06-23-2021]
• COVID-19 serology surveillance [03-11-2021]
• Data visualization [02-16-2021]
• Large-scale geographic seroprevalence surveys [10-02-2020]

ECDC
• Organisation of vector surveillance and control in Europe [12-13-2021]
• Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
• Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 [12:30] [11-29-2021]
• COVID-19 variants: genomically confirmed case numbers [updated 11-29-2021]
• Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
• COVID-19 surveillance guidance - Transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens [10-18-2021]
• Guidance for representative and targeted genomic SARS-CoV-2 monitoring [05-03-2021]

UK
• COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]

Variants – Omicron

Canada
• SARS-CoV-2 variants: national definitions, classifications and public health actions [12-03-2021]

Ontario Ministry of Health
• COVID-19 variant of concern Omicron (B.1.1.529): case, contact and outbreak management interim guidance version 2 [12-17-2021]

CDC
• Omicron variant: what you need to know [12-20-2021]

UK
• Methods for the detection and characterisation of SARS-CoV-2 variants – first update [12-20-2021]
• SARS-CoV-2 Omicron VOC: investigating and managing suspected or confirmed cases [12-02-2021]
Guidance for investigating and managing individuals with a suspected or confirmed infection with Omicron SARS-CoV-2 variant of concern in healthcare settings [12-02-2021]

ECDC
- Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the context of the ongoing Delta VOC transmission in the EU/EEA, 18th update [12-15-2021]
- Threat assessment brief: implications of the further emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) fo the EU/EEA first update [12-02-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00) [11-30-2021]
- Threat Assessment Brief: Implications of the emergence and spread of the SARS CoV-2 B.1.1.529 variant of concern (Omicron) fo the EU/EEA first update [12-02-2021]

WHO
- Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member stats [12-17-2021]

Testing
Canada
- Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [updated 09-08-2021]
- Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [02-23-2021]
- Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

Ontario Ministry of Health
- COVID-19 provincial testing guidance: version 14.0 [updated 11-10-2021]
- Considerations for antigen point-of-care testing, version 7.0 [updated 08-25-2021]
- Point-of-care testing use case guidance version 5.0 [updated 08-25-2021]
- COVID-19 test requisition [06-12-2021]
- Considerations for privately-initiated testing, version 3.0 [05-21-2021]
- COVID-19 guidance: considerations for rapid antigen screening, Version 2.0 [02-17-2021]
- Considerations for employer rapid antigen screening pilot [11-20-2020]
- COVID-19 surveillance testing – guidance regarding retirement homes staff and resident testing [06-09-2020]

Canadian provinces and territories (other than Ontario)
- BC Handout: rapid point-of-care screening in BC [09-00-2021]
- BC Infection prevention and control guidance for test collection and assessment centres [09-09-2021]
- BC Antibody testing (serology) page [no date]
- BC COVID-19: adult & pediatric viral testing guidelines for British Columbia [12-17-2020]
- BC Guideline for the appropriate use of SARS-CoV-2 (COVID-19) antibody (serology) testing [08-14-2020]
CDC
- Guidance for SARS-CoV-2 point-of-care and rapid testing [12-13-2021]
- Testing strategies for SARS-CoV-2 [updated 12-07-2021]
- Overview of testing for SARS-CoV-2 [COVID-19] [10-22-2021]
- CDC’s diagnostic test for COVID-19 only and supplies [10-05-2021]
- Using antibody tests for COVID-19 [09-10-2021]
- Testing guidelines for nursing homes: interim SARS-CoV-2 testing guidelines for nursing home residents and healthcare personnel [09-10-2021]
- Interim guidance on testing healthcare personnel for SARS-CoV-2 [09-10-2021]
- Interim guidance for rapid antigen testing for SARS-CoV-2 [09-09-2021]
- Guidance for health departments about COVID-19 testing in the community [updated 08-30-2021]
- CDC diagnostic tests for covid-19 [updated 08-07-2021]
- Nucleic acid amplification tests (NAATs) [06-14-2021]
- Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [06-14-2021]
- Interim guidance for SARS-CoV-2 testing in correctional and detention facilities [06-07-2021]
- Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]
- SARS-CoV-2 antigen testing in long term care facilities [01-07-2021]
- Serology testing for COVID-19 at CDC [11-03-2020]

UK
- Investigation of SARS-CoV-2 variants of concern: variant risk assessments [updated 12-17-2021]
- SARS-CoV-2 variants of public health interest [updated 12-10-2021]
- How tests and testing kits for coronavirus (COVID-19) work [updated 11-11-2021]
- Coronavirus COVID-19 serology and viral detection tests: technical validation reports [12-01-2021]
- Investigation of SARS-CoV-2 variants of concern: technical briefings [updated 09-17-2021]
- Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021 [07-16-2021]
- Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021 [07-16-2021]
- SARS-CoV-2 variant of concern diagnostic assurance [07-15-2021]
- SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence [10-16-2020]

ECDC
- Methods for the detection and identification of SARS-CoV-2 variants- first update [12-20-2021]
- Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories [12-20-2021]
- Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK [10-26-2021]
- Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings [05-06-2021]
- Considerations for the use of saliva as sample material for COVID-19 testing [05-03-2021]
- Considerations on the use of self-tests for COVID-19 in the EU/EEA [03-17-2021]
- Guidance for COVID-19 quarantine and testing of travellers [03-12-2021]
- Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA [02-16-2021]

Coronavirus Disease 2019 (COVID-19): 01/04/2022 Compiled by PHO Library Services
• Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update [02-15-2021]
• COVID-19 testing strategies and objectives [09-18-2020]
• Objectives for COVID-19 testing in school settings [08-10-2020]

Australia
• PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [11-02-2021]
• PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests [updated 08-23-2021]

Symptoms/Treatment

Canada
• COVID-19 signs, symptoms and severity of disease: a clinician guide [12-09-2021]
• COVID-19 for health professionals: treatments [07-12-2021]
• Non-contact infrared thermometers (NCIT) [01-28-2021]

Ontario Ministry of Health
• COVID-19 Signage questions for businesses and organizations. version 6 [10-25-2021]
• COVID-19 reference document for symptoms v. 8.0 [updated 08-26-2021]
• COVID-19 Patient screening guidance document version 5.0 [updated 08-26-2021]

WHO
• Living guidance for clinical management of COVID-19 [11-23-2021]
• COVID-19 disease in children and adolescents: Scientific brief, 29 September 2021 [09-29-2021]
• Neurology and COVID-19: Scientific brief, 29 September 2021 [09-29-2021]
• Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]
• WHO Living guideline: drugs to prevent COVID-19 [03-02-2021]

Canadian provinces and territories (other than Ontario)
• BC Clinical practice guide for the use of sotrovimab in patients with COVID-19 [12-00-2021]
• BC Antimicrobial and immunomodulatory therapy in adult patients with COVID-19 [11-26-2021]
• BC Pediatric clinical guidance for COVID-19 [09-27-2021]
• BC BC COVID-19 Therapeutic Committee recommendation: therapies for COVID-19 [10-19-2021]
• BC Clinical reference group SBAR: therapies for COVID-19 [updated 10-19-2021]
• BC Approach to assessment and management of long-term COVID-19 symptoms in primary care [08-05-2021]
• BC Updated clinical guidance on multisystem inflammatory syndrome in children (MIS-C): key messages for BC clinicians [07-05-2021]
• BC Guideline for the management of the healthy newborn born to a pregnant mother/individual who is a confirmed or suspect case of COVID-19 [06-10-2021]
• BC Management considerations for an unwell and/or premature newborn who is a contact, under clinical investigation or a confirmed case of COVID-19 [06-10-2021]
• BC Delivery considerations for a newborn born to a mother/individual who is a confirmed case of, or under clinical investigation for, COVID-19 [05-27-2021]
• BC Patient screening tool for direct care interactions [05-03-2021]
• QC COVID-19 symptom-based screening questionnaire [11-22-2021]

CDC
• Standard operating procedure (SOP) for triage of suspected COVID-19 patients in non-US healthcare settings: early identification and prevention of transmission during triage [10-18-2021]
• Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [10-14-2021]
• Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19 [updated 10-14-2021]
• Ending isolation and precautions for people with COVID-19: interim guidance [updated 09-14-2021]
• Ending home isolation for persons with COVID-19 not in healthcare settings [09-14-2021]
• Caring for post-COVID conditions [updated 09-07-2021]
• Care for breastfeeding people [06-17-2021]
• Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
• Clinical care quick reference for COVID-19 [05-17-2021]
• Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) [02-16-2021]
• Assessing risk factors for severe COVID-19 illness [11-30-2020]
• Interim guidance for implementing home care of people not requiring hospitalization for coronavirus disease 2019 (COVID-19) [10-16-2020]

WHO
• Therapeutics and COVID-19 [12-07-2021]
• COVID-19 clinical management: living guidance [11-23-2021]
• Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection [07-15-2021]
• Hypertension and COVID-19 [06-17-2021]
• WHO Information note: COVID-19 considerations for tuberculosis (TB) care [05-05-2021]
• Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]
• WHO COVID-19 clinical care bundle [04-23-2021]
• Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance [08-13-2020]

US NIH
• COVID-19 treatment guidelines [10-27-2021]

UK
• COVID-19: migrant health guide [updated 12-20-2021]
• COVID-19: long-term health effects [04-30-2021]
COVID-19 Diagnosis in Children

Canada
- COVID-19 signs, symptoms and severity of disease: multisystem inflammatory syndrome - children (MIS-C) [modified 12-09-2021]

Ontario
- Appendix 8: cases with positive COVID-19 serology results and management of cases with multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 [02-18-2021]

WHO

CDC
- Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) [05-20-2021]
- Information for pediatric healthcare providers [12-30-2020]
- Evaluation and management considerations for neonates at risk for COVID-19 [12-08-2020]

Other
- BC Children with immune compromise [11-30-2021]
- BC Pediatric clinical guidance for COVID-19 [09-27-2021]
- BC Guidance for newborn care, resuscitation procedures and lactation [06-11-2021]
- BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic [05-12-2021]

Post-COVID-19 Condition

Canada
- Post COVID-19 condition [09-24-2021]

Ontario
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

WHO
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]
CDC
- Caring for post-COVID conditions [09-07-2021]
- Post-COVID conditions: information for healthcare providers [07-09-2021]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]

UK
- COVID-19: long-term health effects [04-30-2021]

Case Investigation & Contact Tracing
Canada
- Public health management of cases and contacts associated with COVID-19 [12-15-2021]

Ontario
- COVID-19 fully immunized and previously positive individuals: case, contact and outbreak management interim guidance v 3 [10-12-2021]
- Management of cases and contacts of COVID-19 in Ontario (version 13.0) [08-11-2021]
- Appendix 11: high risk contact flow chart [no date]
- Appendix 9: management of individuals with point-of-care results version 6.0 [08-25-2021]
- Appendix 8: cases with positive COVID-19 serology results and management of cases with multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 [02-18-2021]
- Appendix 10: case & contact management COVID-19 surge support model (pilot) [01-21-2021]

Canadian provinces and territories (other than Ontario)

WHO
- Considerations for quarantine of contacts of COVID-19 cases [06-25-2021]
- Operational guide for engaging communities in contact tracing [05-28-2021]
- Contact tracing in the context of COVID-19 [02-01-2021]
- Online global consultation on contact tracing for COVID-19, 9-11 June 2020 [01-22-2021]
- Ethical considerations to guide the use of digital proximity tracking technologies for COVID-19 contact tracing [05-28-2020]

CDC
- Quarantine and isolation [12-09-2021]
- COVID-19 Contact tracing communications toolkit for health departments [11-05-2021]
- Considerations for case investigation and contact tracing in K-12 schools and institutions of higher education (IHEs) [10-19-2021]
- Contact tracer’s interview tool: notifying people about an exposure to COVID-19 [10-19-2021]
- Contact tracing resources for health departments [09-23-2021]
- Operational considerations for adapting a contact tracing program to respond to the COVID-19 pandemic in non-US Settings [09-22-2021]
- Ending home isolation for persons with COVID-19 not in healthcare settings [09-14-2021]
- Contact Tracing for COVID-19 [02-25-2021]
• Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-19-2021]
• Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-18-2021]
• Scaling up staffing roles in case investigation and contact tracing [12-03-2020]
• Prioritizing COVID-19 contact tracing mathematical modeling methods and findings [11-23-2020]
• Investigating a COVID-19 case [11-23-2020]
• Digital contact tracing tools [05-26-2020]

UK

• COVID-19: guidance for households with possible coronavirus infection [updated 12-16-2021]
• Guidance for contacts of people with confirmed coronavirus (COVID-19) infection who do not live with the person [updated 12-16-2021]
• COVID-19: investigation and initial clinical management of possible cases [12-14-2020]

ECDC

• Contact tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – 4th update [10-28-2021]
• Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions [06-28-2021]
• Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK [06-12-2020]
• Mobile applications in support of contact tracing for COVID-19 - A guidance for EU EEA Member States [06-10-2020]

Infection Prevention and Control

PHAC / Health Canada

• Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [12-20-2021]
• At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [updated 12-15-2021]
• Coronavirus disease (COVID-19): prevention and risks [modified 12-14-2021]
• COVID-19 medical masks and N95 respirators: overview [updated 11-29-2021]
• Infection prevention and control for COVID-19: interim guidance for home care settings [modified 11-02-2021]
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [09-16-2021]
• COVID-19: guidance on indoor ventilation during the pandemic [01-18-2021]

Back to Top
Ontario

- Infection Prevention and Control Hubs [11-10-2020]

Canadian provinces and territories (other than Ontario)

- BC Infection prevention and control guidance on SARS-CoV-2 variants of concern [10-12-2021]
- BC Infection prevention and control (IPC) protocol during in-hospital Code Blue for adult patients [09-27-2021]
- BC Discussion on risk of SARS-CoV-2 aerosol transmission in health care settings [09-08-2021]
- BC Infection prevention and control guidance for community-based physicians, nursing professionals and midwives in clinic settings [09-01-2021]
- BC Infection prevention and control policy for all health authorities [09-01-2021]
- BC Infection prevention and control guidance for long-term care and seniors' assisted living settings [08-30-2021]
- BC Infection prevention and control: guidance for acute health-care settings [08-30-2021]
- BC Environmental cleaning and disinfectants for clinic settings poster [06-02-2021]
- BC PPE audit tool [03-19-2021]
- BC COVID-19: personal protective equipment recommendations for endotracheal intubation of suspected or confirmed COVID-19 patients in critical care and emergency departments [01-14-2021]
- QC Support document for the Advisory Committee on COVID-19 transmission in school and healthcare environments and on the role of ventilation [09-08-2021]
- QC FAQ: COVID-19 transmission modes and measures to prevent and control risk, including the role of ventilation [no date]
- QC COVID-19: Use of air conditioners and electric fans during heat waves [08-04-2021]
- QC SARS-CoV-2 transmission: findings and proposed terminology [07-09-2021]
- QC COVID 19: surface cleaning and disinfection [06-14-2021]
- QC Aerosol-generating medical interventions on suspected and confirmed cases of COVID-19 [03-17-2021]
- QC COVID-19: infection prevention and control measures for hemodialysis units [02-26-2021]

WHO

- COVID-19: infection prevention and control (IPC) [updated 12-17-2021]
- Annex to Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [10-01-2021]
- Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed [07-12-2021]
- Reducing public health risks associated with the sale of live wild animals of mammalian species in traditional food markets [04-12-2021]
- Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]
- **Mask use in the context of COVID-19: Interim Guidance** [12-01-2020]
- **Readiness for influenza during the COVID-19 pandemic** [11-06-2020]
- **Water, sanitation, hygiene, and waste management for SARS-CoV-2, the virus that causes COVID-19** [07-29-2020]

**CDC**
- **Considerations for inpatient obstetric healthcare settings** [11-19-2021]
- **Cleaning and disinfecting your facility: every day and when someone is sick** [11-15-2021]
- **Strategies for optimizing the supply of N95 respirators** [09-16-2021]
- **Strategies for optimizing the supply of eye protection** [09-13-2021]
- **Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes** [09-10-2021]
- **Considerations for optimizing the supply of powered air-purifying respirators (PAPRs)** [11-03-2020]

**ECDC**
- **Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination** [03-29-2021]
- **Infection prevention and control and preparedness for COVID-19 in healthcare settings- sixth update** [02-09-2021]
- **Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU/EEA - Second update** [12-10-2020]
- **Guidelines for the use of non-pharmaceutical measures to delay and mitigate the impact of 2019-nCoV** [09-24-2020]

**UK**
- **Coronavirus (COVID-19): safer public places - managing public outdoor settings** [updated 12-13-2021]
- **COVID-19: guidance for stepdown of infection control precautions and discharging COVID-19 patients from hospital to home settings** [updated 12-14-2021]
- **Technical specifications for personal protective equipment (PPE)** [11-30-2021]
- **COVID-19: infection prevention and control (IPC)** [12-21-2021]
- **Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19)** [09-15-2021]
- **COVID-19: personal protective equipment use for aerosol generating procedures** [08-21-2020]
- **COVID-19: personal protective equipment use for non-aerosol generating procedures** [08-21-2020]

**Australia**
- **CDNA guidelines for the prevention, control and public health management of COVID-19 outbreaks in correctional and detention facilities in Australia** [10-07-2021]
- **Coronavirus (COVID-19) guidelines for infection prevention and control in residential care facilities** [06-16-2021]
- **Guidance on the use of personal protective equipment (PPE) in hospitals during the COVID-19 outbreak** [06-10-2021]
ICEG guidelines on cleaning and disinfection of protective eyewear in health and residential care facilities [06-10-2021]

CDNA national guidelines for the prevention, control and public health management of COVID-19 outbreaks in residential care facilities in Australia [updated 06-10-2021]

CDNA national guidelines for the prevention and management of COVID-19 outbreaks in disability residential services - the disability supplement [06-10-2021]

Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health


Canada

- COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

Canadian provinces and territories (other than Ontario)

- BC Entrance screening tool for health care facilities [11-05-2021]
- BC Overview of visitors in acute care [11-01-2021]
- BC Visitor restrictions in effect poster [11-01-2021]
- BC Recommendations for risk assessment and management of health-care worker exposures to COVID-19 patients [09-22-2021]
- BC Primary care summary: what is the ethical duty of health-care workers to provide care during the COVID-19 pandemic? [09-03-2021]
- BC COVID-19 ethics analysis: intervening when patients or residents pose a risk of COVID-19 transmission to others [01-18-2021]
- BC Management of PPE-related skin damage for health care workers v1.1 [no date]

WHO

- Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: Interim guidance [07-12-2021]
- COVID-19: Occupational health and safety for health workers [02-02-2021]

CDC

- Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [09-10-2021]

UK

- COVID-19: management of staff and exposed patients and residents in health and social care settings [updated 12-15-2021]
- Contract tracing in the European Union: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases – fourth update [10-28-2021]
First Responders, Dentistry, Pharmacy, and Allied Health

Ontario Ministry of Health


PHAC

- Evidence to support safe return to clinical practice by oral health professionals in Canada during the COVID-19 pandemic: a report prepared for the Office of the Chief Dental Officer of Canada Ontario Ministry of Health [09-21-2021]

WHO

- Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19): interim guidance [02-17-2021]

CDC

- Evaluation for SARS-CoV-2 testing in animals [10-12-2021]
- COVID-19 considerations for school sealant programs [07-13-2021]

UK

- COVID-19: guidance for first responders [updated 12-20-2021]
- COVID-19: guidance for ambulance services [updated 11-30-2021]

Other

- COVID-19: managing infection risks during in-person dental care Royal College of Dental Surgeons of Ontario [09-20-2021]
- COVID-19: guidance for the use of teledentistry Royal College of Dental Surgeons of Ontario [no date]

Death Services

Ontario

- ON Bereavement Authority of Ontario COVID-19 [10-27-2021]

Canada

- Interim guidance: death care services and handling of dead bodies during the coronavirus disease (COVID-19) pandemic [09-23-2020]
- Interim guidance: management of mass fatalities during the coronavirus disease (COVID-19) pandemic [04-25-2020]

WHO

- Infection prevention and control for the safe management of a dead body in the context of COVID-19: interim guidance [09-04-2020]

CDC

- Recommendations for Tribal ceremonies & gatherings [09-30-2021]
Collection and submission of postmortem specimens from deceased persons with known or suspected COVID-19: interim guidance [12-02-2020]
FAQs for medicolegal death investigators [11-02-2020]

UK
COVID-19: guidance for arranging or attending a funeral or commemorative event [updated 12-16-2021]

Other
QC COVID-19: preventive and protective measures for funeral services businesses [07-30-2021]

Congregate Living (including Long-Term Care, Prisons, and Shelters)
Ontario Ministry of Health
COVID-19 screening tool for long-term care homes and retirement homes: version 7 [12-09-2021]
COVID-19 guidance: long-term care homes and retirement homes for public health units [07-23-2021]
Retirement homes policy to implement directive #3 [07-16-2021]
COVID-19 guidance: home and community care providers: version 6 [05-21-2021]

PHAC
Guidance for providers of services for people experiencing homelessness (in the context of COVID-19) [modified 12-20-2021]
COVID-19: guidance on pets and long-term care homes [07-20-2021]
Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO
Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC
How to protect yourself and others [updated 11-29-2021]
Interim guidance on people experiencing unsheltered homelessness [11-04-2021]
Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 (COVID-19) [11-03-2021]
Correctional and detention facilities [10-19-2021]
Infection control for nursing homes [09-10-2021]
• Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-30-2021]
• Investigating cases in homeless shelters [08-13-2021]
• Interim guidance on management of coronavirus disease 2019 (covid-19) in correctional and detention facilities [06-09-2021]
• Recommendations for quarantine duration in correctional and detention Facilities [06-09-2021]
• Guidance for group homes for individuals with disabilities [05-17-2021]
• Interim guidance on management of coronavirus disease 2019 (covid-19) in correctional and detention facilities [06-09-2021]
• Recommendations for quarantine duration in correctional and detention Facilities [06-09-2021]
• Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]

UK
• COVID-19: guidance for hostels or day centres for people rough sleeping [updated 12-15-2021]
• COVID-19: provision of night shelters [updated 12-13-2021]
• Management of acute respiratory illness in prisons and places of detention [updated 12-10-2021]
• Coronavirus (COVID-19) and prisons [12-09-2021]
• Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
• Preventing and controlling outbreaks of COVID-19 in prisons and places of detention [09-09-2021]
• Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.0 [09-03-2021]
• COVID-19: how to work safely in domiciliary care in England [08-26-2021]
• COVID-19: National framework for prison regimes and services [08-18-2021]
• COVID-19: admission and care of people in care homes [08-17-2021]
• COVID-19: how to work safely in care homes [08-16-2021]
• COVID-19 guidance for prison settings v 1.0 [07-16-2021]
• Infection prevention and control and surveillance for coronavirus disease (COVID-19) in prisons in EU/EEA countries and the UK [07-03-2020]
• Guidance on infection prevention and control of COVID-19 in migrant and refugee reception and detention centres in the EU/EEA and the UK [06-15-2020]
• Infection control in prisons and places of detention [07-01-2011]

Canadian provinces and territories (other than Ontario)
• BC Social visiting guidelines for long term care and assisted living facilities [11-04-2021]
• BC Visitor guidance for long-term care and seniors' assisted living [10-12-2021]

Other
• CSC Testing of inmates in federal correctional institutions for COVID-19 [updated 12-20-2021]
• BC COVID-19 Infection Prevention and Control: guidance for long-term care and seniors’ assisted living settings [08-30-2021]
• Australia CDNA guidelines for the prevention, control and public health management of COVID-19 outbreaks in correctional and detention facilities in Australia [10-07-2021]
Section III: Guidelines for the Community

Travel, Transport & Borders

Ontario Ministry of Health

- Travelling during COVID-19 [09-23-2021]
- Guidance for public transit agencies and passengers in response to COVID-19 [05-10-2021]

Canada

- Official global travel advisories [updated daily]
- COVID-19: travel, testing, quarantine and borders [updated 12-17-2021]
- Provincial and territorial restrictions [updated 11-26-2021]
- COVID-19: passenger transport where you may have been exposed [11-17-2021]
- Guidance material for air operators managing travellers during the check-in procedure for flights departing from an aerodrome in Canada [11-16-2021]
- Federal safety guidance to protect drivers and limit the spread of COVID-19 in commercial vehicle operations [06-24-2021]

CDC

- COVID-19 travel recommendations by destination [updated 12-20-2021]
- Required testing before air travel to the US [updated 12-17-2021]
- Travel-associated exposures [updated 12-02-2021]
- Public Health Guidance for Potential COVID-19 Exposure Associated with Travel [updated 12-02-2021]

WHO

- WHO public health checklist for controlling the spread of COVID-19 in ships, sea ports and inland ports [10-00-2021]

ECDC

- COVID-19 aviation health safety protocol: operational guidelines for the management of air passengers and aviation personnel in relation to the COVID-19 pandemic [06-17-2021]

UK

- COVID-19: safer travel guidance for passengers [updated 12-21-2021]
- COVID-19: taxis and PHVs [updated 12-20-2021]
- Travel to England from another country during coronavirus (COVID-19) [updated 12-20-2021]
- Coronavirus (COVID-19): taxis and PHVs [updated 12-20-2021]
- Coronavirus (COVID-19): domestic cruise ship travel [12-14-2021]
- COVID-19: general aviation [12-14-2021]
- Coronavirus (COVID-19): testing before you travel to England [updated 12-13-2021]
- COVID-19: safer transport guidance for operators and people who work in or from vehicles [updated 12-10-2021]
- COVID-19: safer air travel for passengers [updated 12-07-2021]
- Coronavirus (COVID-19): safer aviation guidance for operators [07-19-2021]
- COVID-19: safer aviation guidance for operators [07-19-2021]

Other
- Emergency response plan and action checklist for use by air carriers in the event of a public health emergency [no date]

Schools / Childcare
Ontario Ministry of Health
- COVID-19: health, safety and operational guidance for schools (2021-2022) [08-26-2021]
- COVID-19: health and safety measures for child care [08-17-2021]
- COVID-19 safety guidelines for: overnight camps. version 3.0 [08-12-2021]
- COVID-19 guidance: school outbreak management [08-11-2021]

PHAC
- Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [modified 12-10-2021]
- COVID-19: organized summer activities for children and youth [12-16-2021]
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [15-16-2021]

CDC
- Schools and childcare programs [12-17-2021]
- COVID-19 Guidance for Operating Early Care and Education/Child Care Programs [updated 11-10-2021]
- Guidance for COVID-19 Prevention in K-12 Schools [updated 11-05-2021]
- Considerations for institutions of higher education [updated 11-04-2021]

UK
- Coronavirus (COVID-19) test kits for children's homes [updated 12-20-2021]
- Higher education providers: coronavirus (COVID-19) [updated 12-14-2021]
- Transport to schools and colleges during the COVID-19 pandemic [updated 12-14-2021]
- Protective measures for holiday or after-school clubs and other out-of-school settings for children during the coronavirus (COVID-19) outbreak [updated 12-14-2021]
- Guidance for parents and carers of children attending out-of-school settings during the coronavirus (COVID-19) outbreak [updated 12-14-2021]
- Actions for schools during the coronavirus outbreak [updated 12-14-2021]
- Actions for early years and childcare providers during the coronavirus (COVID-19) outbreak [updated 12-14-2021]
- Special schools and other specialist settings: coronavirus (COVID-19) [updated 12-14-2021]
- What parents and carers need to know about early years providers, schools and colleges during COVID-19 [updated 12-14-2021]
- Providing school meals during coronavirus (COVID-19) outbreak [10-05-2021]

Other
• QC Support document for the advisory committee on COVID-19 transmission in school and healthcare environments and on the role of ventilation [09-08-2021]

Mental Health /Addiction /Inequity

Ontario Ministry of Health
• COVID-19: mental health resources for camp operators version 1.0 [07-13-2021]
• Guidance for consumption and treatment services sites: version 2 [04-16-2020]
• COVID-19 Guidance: mental health and addictions service providers in community settings: version 2 [09-24-2020]

PHAC
• Helping people who use substances during the COVID-19 pandemic [07-06-2021]

Provinces & Territories (excluding Ontario)
• AB Harm reduction and COVID-19: guidance document for community service providers [12-08-2020]
• QC COVID-19: tackling social isolation and loneliness among seniors in a pandemic context [10-28-2020]
• BC COVID-19: provincial episodic overdose prevention service (e-OPS) protocol [06-26-2020]
• BC COVID-19: harm reduction and overdose response [07-08-2020]

WHO
• Rise, respond, recover: renewing progress on women's, children's and adolescent's health in the era of COVID-19 [12-00-2021]
• Social isolation and loneliness among older people: advocacy brief [07-29-2021]
• Smoking and COVID-19 [06-30-2020]
• Addressing violence against children, women and older people during the COVID-19 pandemic: key actions [06-18-2020]
• COVID-19 and violence against women: what the health sector / system can do [04-07-2020]

CDC / SAMHSA
• Substance abuse and mental health training and technical assistance related to COVID-19 [08-16-2021]
• Virtual recovery resources [07-00-21]
• Disaster planning handbook for behavioural health service programs [03-00-2021]
• Interim guidance for syringe services programs [05-15-2020]
• Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020 [05-07-2020]
• Considerations for crisis centers and clinicians in managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic: March 19, 2020 [03-19-2020]
• Intimate partner violence and child abuse considerations during COVID-19 [no date]

UK
- Domestic abuse: how to get help [11-11-2021]
- Alcohol and drug misuse prevention and treatment guidance [08-11-2021]
- Every Mind Matters: looking after your mental health [no date]

Other
- Public health ethics and COVID-19: selected resources [11-00-2021]
- Risk mitigation in the context of dual public health emergencies. Version 1.5 [03-00-20]
- COVID-19: guidance for individuals experiencing abuse York University (Ontario) [no date]

Community

Ontario Ministry of Health
- Organized social events and public gatherings [10-22-2021]
- Extra-curricular activities and community use of schools [08-26-2021]
- Guidance on community emergency evacuations: version 2 [07-06-2021]

PHAC
- COVID-19: organized summer activities for children and youth [12-16-2021]
- Individual and community-based measures to mitigate the spread of coronavirus disease (COVID-19) in Canada [12-16-2021]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]
- COVID-19: plan a safe holiday or celebration [12-09-2021]
- COVID-19: advice for gatherings, events and celebrations [12-09-2021]
- Reducing COVID-19 risk in community settings: A tool for operators [08-09-2021]

WHO
- Key planning recommendations for mass gatherings in the context of COVID-19 [11-04-2021]
- Safe Eid al Adha practices in the context of COVID-19 [07-13-2021]

CDC
- Information about COVID-19, pets, and other animals [12-21-2021]
- Breastfeeding & caring for newborns [updated 12-09-2021]
- Activities, Gatherings & Holidays [12-09-2021]
- Recommendations for Tribal ceremonies & gatherings [09-30-2021]
- Community, Work, and School [08-24-2021]
- Guidance for adult day services centers [08-12-2021]
- Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-04-2021]
- Operational considerations for community isolation centers [08-09-2021]
- COVID-19 response health equity strategy: accelerating progress towards reducing COVID-19 disparities and achieving health equity [08-21-2020]
- Considerations for owners and operators of multifamily housing including populations at increased risk for complications from COVID-19 [05-05-2021]

UK
- COVID-19: guidance for households with possible coronavirus infection [updated 12-16-2021]
- COVID-19: guidance for providers of accommodation for asylum seekers [updated 12-14-2021]
- Coronavirus: how to stay safe and help prevent the spread [updated 12-14-2021]
- Guidance on coronavirus (COVID-19) measures for grassroots sport participants, providers and facility operators [12-13-2021]
- Moving home during coronavirus (COVID-19) [12-13-2021]
- COVID-19: guidance for the safe use of places of worship [12-10-2021]
- Supported living services during coronavirus (COVID-19) [11-22-2021]

Canadian provinces and territories (other than Ontario)
- QC COVID 19: Surface cleaning and disinfection [06-14-2021]
- BC Guideline for the management of the healthy newborn born to a pregnant mother/individual who is confirmed or suspect case of COVID-19 [06-10-2021]

Australia
- Early aero-medical evacuation of COVID-19 cases and contacts from remote communities [08-20-2020]

Businesses/Workplaces

Ontario Ministry of Health
- COVID-19 worker and employee screening [12-21-2021]
- COVID-19 customer screening [12-21-2021]
- COVID-19 and workplace health and safety [12-15-2021]
- COVID-19 signage questions for businessess and organizations [10-25-2021]
- Proof of vaccination guidance for businesses and organizations under the reopening act. Version 4 [11-16-2021]
- Restaurant and food services health and safety during COVID-19 [10-08-2021]
- COVID-19 guidance: workplace outbreaks v2.0 [10-05-2021]

PHAC
- Reducing COVID-19 risk in community settings: a tool for operators [08-09-2021]

WHO
- Preventing and mitigating COVID-19 at work [05-19-2021]

CDC
- Workplaces & businesses: plan, prepare and respond [10-18-2021]
- Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [updated 08-13-2021]

UK

Other
• BC Guidance on return to work for health care workers with confirmed or suspected COVID-19 [09-22-2021]
• BC Guidance for outside dining spaces based on the Provincial Health Officer’s order to food and liquor serving premises [04-23-2021]

Masks (Non-Medical)

Ontario Ministry of Health
• Face coverings and face masks [09-16-2021]

PHAC
• COVID-19 mask use: advice for community settings [updated 12-09-2021]

WHO
• What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? [00-00-2021]
• Advice on the use of masks in the context of COVID-19 [12-01-2020]

CDC
• Your guide to masks [10-25-2021]
• Use of masks to help slow the spread of COVID-19 [08-12-2021]

ECDC
• Using face masks in the community: first update – effectiveness in reducing transmission of COVID-19 [02-15-2021]
• Use of gloves in healthcare and non-healthcare settings in the context of the COVID-19 pandemic [07-02-2020]

UK
• Face coverings: when to wear one, exemptions, and how to make one [updated 12-10-2021]
• The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]

Other
• BC Face coverings (COVID-19) [updated 12-03-2021]